Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28290422 | 1.00 | IDO1 (0.37) | IDO1LMNAAAK1ATMSMN1; SMN2 | |
| SCHEMBL18427958 | 1.00 | IDO1 (0.37) | IDO1LMNAAAK1ATMSMN1; SMN2 | |
| SCHEMBL28524652 | 0.92 | AAK1 (0.35) | IDO1LMNAAAK1ATMSMN1; SMN2 | |
| SCHEMBL28524651 | 0.92 | AAK1 (0.35) | IDO1LMNAAAK1ATMSMN1; SMN2 | |
| SCHEMBL16970590 | 0.92 | AAK1 (0.35) | IDO1LMNAAAK1ATMSMN1; SMN2 | |
| SCHEMBL16982773 | 0.91 | AAK1 (0.36) | LMNAAAK1ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL18445860 | 0.90 | IDO1 (0.40) | IDO1LMNAAAK1ATMSMN1; SMN2 | |
| SCHEMBL16974981 | 0.90 | IDO1 (0.40) | IDO1LMNAAAK1ATMSMN1; SMN2 | |
| SCHEMBL16974985 | 0.90 | IDO1 (0.40) | IDO1LMNAAAK1ATMSMN1; SMN2 | |
| SCHEMBL28527873 | 0.90 | IDO1 (0.35) | IDO1LMNAAAK1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102195-B1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES INC (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-106163509-B | β -substituted β -amino acids and analogs as chemotherapeutic agents | 夸德里加生物科学公司 | 2019-05-03 | — | — | CN | disclosed |
| US-10245246-B2 | β-substituted β-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10034847-B2 | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180078517-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2018-03-22 | — | — | US | disclosed |
| US-9861599-B2 | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| EP-3102195-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | Quadriga Biosciences, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160346240-A1 | METHODS OF CHEMOTHERAPY USING CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS | QUADRIGA BIOSCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160296484-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160289172-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160185710-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-06-30 | — | — | US | disclosed |
| WO-2015117147-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289172-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | IDO1 1381/4885LMNA 3813/4885AAK1 1370/4885 |
| US-10245246-B2 | β-substituted β-amino acids and analogs as chemotherapeutic agents | SLC7A1, SLC3A2, SLC1A5 | IDO1 1409/4885LMNA 3876/4885AAK1 1360/4885 |
| US-20160346240-A1 | METHODS OF CHEMOTHERAPY USING CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS | BCAT1, CDC25C, BCAT2 | IDO1 1881/4885LMNA 861/4885AAK1 2098/4885 |
| US-20160296484-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | IDO1 1381/4885LMNA 3813/4885AAK1 1370/4885 |
| US-20180078517-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | IDO1 1381/4885LMNA 3813/4885AAK1 1370/4885 |
| US-10034847-B2 | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | SLC7A1, SLC3A2, SLC1A5 | IDO1 1381/4885LMNA 3813/4885AAK1 1370/4885 |
| US-20160185710-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | IDO1 1381/4885LMNA 3813/4885AAK1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.